<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02223559</url>
  </required_header>
  <id_info>
    <org_study_id>25-593 ex 12/13</org_study_id>
    <nct_id>NCT02223559</nct_id>
  </id_info>
  <brief_title>Non-invasive Assessment of Pulmonary Artery Pressure</brief_title>
  <official_title>Non-invasive Assessment of Pulmonary Artery Pressure and Right Ventricular Function in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Bank of Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig Boltzmann Institute for Lung Vascular Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The assessment of pulmonary artery pressure (PAP) and parameters describing right ventricular&#xD;
      function stand in the focus of the diagnosis and clinical management of pulmonary&#xD;
      hypertension (PH). Right heart catheterization (RHC) is the gold standard method to measure&#xD;
      PAP and to provide hemodynamic information on right ventricular function. However, due to its&#xD;
      invasive nature, RHC is not optimal for screening and for close monitoring of the disease.&#xD;
      Therefore, the development of non-invasive methods providing reliable PAP measurements and&#xD;
      right ventricular functional parameters would be of major benefit.&#xD;
&#xD;
      Today, the most often used comprehensive non-invasive method for these purposes is&#xD;
      echocardiography. However, the method has limitations; in many cases PAP is significantly&#xD;
      under- or overestimated - especially in subjects with co-existing pulmonary diseases.&#xD;
      Regarding right ventricular function, although novel echocardiography parameters appear to be&#xD;
      promising, they have not yet been evaluated in all forms of PH.&#xD;
&#xD;
      Another emerging non-invasive method is cardiac magnetic resonance imaging (MRI). MRI is&#xD;
      considered to be as gold standard for the non-invasive assessment of right ventricular&#xD;
      function. In addition, our group showed that with a special approach (&quot;vortex method&quot;), MRI&#xD;
      enables the determination of PAP with physiologic accuracy, but the method has not yet been&#xD;
      validated systematically in different forms of PH.&#xD;
&#xD;
      All patients undergoing right heart catheterization in our clinic are candidates for the&#xD;
      study. Excluded will be patients not eligible for MRI or declining to take part in the study.&#xD;
      MRI and Echocardiography will be performed within two weeks of the RHC.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
        1. MRI is superior to echocardiography to non-invasively determine mean PAP in a broad&#xD;
           collective of patients with PH of diverse ethology.&#xD;
&#xD;
        2. MRI derived right ventricular functional parameters correlate better to invasive&#xD;
           measurements and to established prognostic parameters than echocardiography derived&#xD;
           right ventricular functional parameters.&#xD;
&#xD;
        3. Novel right ventricular tissue Doppler parameters add substantially to &quot;classical&quot;&#xD;
           echocardiography parameters to describe right ventricular function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mean pulmonary artery pressure</measure>
    <time_frame>at baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>right ventricular function parameters</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>right heart catheterization patients</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma samples will be retrained&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing right heart catheterization due to clinical reasons&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: patients undergoing right heart catheterization due to clinical reasons&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria: patients not eligible for MRI, patients not agreeing with investigation&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Olschewski, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

